Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

de Zeeuw, D, Akizawa, T, Agarwal, R, Audhya, P, Bakris, GL, Chin, M, Krauth, M, Lambers Heerspink, HJ, Meyer, CJ, McMurray, JJ, Parving, H-H, Pergola, PE, Remuzzi, G, Toto, RD, Vaziri, ND, Wanner, C, Warnock, DG, Wittes, J & Chertow, GM 2013, 'Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)' American Journal of Nephrology, bind 37, nr. 3, s. 212-22. https://doi.org/10.1159/000346948

APA

CBE

de Zeeuw D, Akizawa T, Agarwal R, Audhya P, Bakris GL, Chin M, Krauth M, Lambers Heerspink HJ, Meyer CJ, McMurray JJ, Parving H-H, Pergola PE, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Warnock DG, Wittes J, Chertow GM. 2013. Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). American Journal of Nephrology. 37(3):212-22. https://doi.org/10.1159/000346948

MLA

Vancouver

Author

de Zeeuw, Dick ; Akizawa, Tadao ; Agarwal, Rajiv ; Audhya, Paul ; Bakris, George L ; Chin, Melanie ; Krauth, Melissa ; Lambers Heerspink, Hiddo J ; Meyer, Colin J ; McMurray, John J ; Parving, Hans-Henrik ; Pergola, Pablo E ; Remuzzi, Giuseppe ; Toto, Robert D ; Vaziri, Nosratola D ; Wanner, Christoph ; Warnock, David G ; Wittes, Janet ; Chertow, Glenn M. / Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes : the Occurrence of Renal Events (BEACON). I: American Journal of Nephrology. 2013 ; Bind 37, Nr. 3. s. 212-22.

Bibtex

@article{8e0d5f2c4beb4b04a57c8bf28ae8cc84,
title = "Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)",
abstract = "Chronic kidney disease (CKD) associated with type 2 diabetes mellitus constitutes a global epidemic complicated by considerable renal and cardiovascular morbidity and mortality, despite the provision of inhibitors of the renin-angiotensin-aldosterone system (RAAS). Bardoxolone methyl, a synthetic triterpenoid that reduces oxidative stress and inflammation through Nrf2 activation and inhibition of NF-κB was previously shown to increase estimated glomerular filtration rate (eGFR) in patients with CKD associated with type 2 diabetes mellitus. To date, no antioxidant or anti-inflammatory therapy has proved successful at slowing the progression of CKD.",
author = "{de Zeeuw}, Dick and Tadao Akizawa and Rajiv Agarwal and Paul Audhya and Bakris, {George L} and Melanie Chin and Melissa Krauth and {Lambers Heerspink}, {Hiddo J} and Meyer, {Colin J} and McMurray, {John J} and Hans-Henrik Parving and Pergola, {Pablo E} and Giuseppe Remuzzi and Toto, {Robert D} and Vaziri, {Nosratola D} and Christoph Wanner and Warnock, {David G} and Janet Wittes and Chertow, {Glenn M}",
note = "Copyright {\circledC} 2013 S. Karger AG, Basel.",
year = "2013",
doi = "10.1159/000346948",
language = "English",
volume = "37",
pages = "212--22",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S./Karger AG",
number = "3",

}

RIS

TY - JOUR

T1 - Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes

T2 - the Occurrence of Renal Events (BEACON)

AU - de Zeeuw, Dick

AU - Akizawa, Tadao

AU - Agarwal, Rajiv

AU - Audhya, Paul

AU - Bakris, George L

AU - Chin, Melanie

AU - Krauth, Melissa

AU - Lambers Heerspink, Hiddo J

AU - Meyer, Colin J

AU - McMurray, John J

AU - Parving, Hans-Henrik

AU - Pergola, Pablo E

AU - Remuzzi, Giuseppe

AU - Toto, Robert D

AU - Vaziri, Nosratola D

AU - Wanner, Christoph

AU - Warnock, David G

AU - Wittes, Janet

AU - Chertow, Glenn M

N1 - Copyright © 2013 S. Karger AG, Basel.

PY - 2013

Y1 - 2013

N2 - Chronic kidney disease (CKD) associated with type 2 diabetes mellitus constitutes a global epidemic complicated by considerable renal and cardiovascular morbidity and mortality, despite the provision of inhibitors of the renin-angiotensin-aldosterone system (RAAS). Bardoxolone methyl, a synthetic triterpenoid that reduces oxidative stress and inflammation through Nrf2 activation and inhibition of NF-κB was previously shown to increase estimated glomerular filtration rate (eGFR) in patients with CKD associated with type 2 diabetes mellitus. To date, no antioxidant or anti-inflammatory therapy has proved successful at slowing the progression of CKD.

AB - Chronic kidney disease (CKD) associated with type 2 diabetes mellitus constitutes a global epidemic complicated by considerable renal and cardiovascular morbidity and mortality, despite the provision of inhibitors of the renin-angiotensin-aldosterone system (RAAS). Bardoxolone methyl, a synthetic triterpenoid that reduces oxidative stress and inflammation through Nrf2 activation and inhibition of NF-κB was previously shown to increase estimated glomerular filtration rate (eGFR) in patients with CKD associated with type 2 diabetes mellitus. To date, no antioxidant or anti-inflammatory therapy has proved successful at slowing the progression of CKD.

U2 - 10.1159/000346948

DO - 10.1159/000346948

M3 - Journal article

VL - 37

SP - 212

EP - 222

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - 3

ER -

ID: 38879053